a r t I C l e S HD is an autosomal dominant neurodegenerative disease caused by a polyglutamine-encoding CAG repeat expansion in exon 1 of the huntingtin gene (HTT). Although huntingtin is ubiquitously expressed in most tissues 1,2 , the neuropathology of HD is characterized by relatively selective neuronal cell death in the striatum and cortex 3 . Wild-type huntingtin has a crucial role in the development of the nervous system and is protective against various forms of cytotoxicity, including neurotoxicity induced by mutant huntingtin (mHTT) 4, 5 . The cytotoxicity of mHTT has been proposed to be the result of several mechanisms, including the disruption of axonal transport, mitochondrial dysfunction, imbalance in calcium homeostasis and excitotoxicity, altered proteolysis, impairment of the ubiquitin proteasome system, and altered transcription 6 . The balance of expression between mutant and wild-type huntingtin may be an important modulator of pathogenesis and disease progression in HD.
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In HD, the length of the CAG repeat in the expanded HTT disease allele inversely correlates with age of onset (AO). Although CAG repeat length accounts for a large proportion of the variation in AO 7 , there is substantial variability observed between expected and observed AO in HD patients 8 . HD patients with identical CAG repeat lengths, particularly those with CAG sizes between 40-44, can have AOs that differ by more than 20 years 9 . Increasingly, disease-associated non-coding single-nucleotide polymorphisms (SNPs) are being identified as potential modifiers of disease progression 10 . Cis-acting regulatory SNPs (rSNPs) can alter the binding affinity of transcription factors to their binding sites, changing gene transcriptional activity and consequently modifying disease phenotype or progression. Other modifiers, such as interacting genes and environmental factors, likely also contribute to the variation in AO observed in HD 11 . Both cis-and trans-acting factors that regulate HTT gene expression are likely to affect AO and disease progression in HD.
Genetic variation in regulatory sequences can affect the binding of transcription factors (TFs) and alter the rate of transcription; such regulatory sequence variations could affect the expression of the HTT gene, leading to functional consequences in HD. The expression levels of both wild-type huntingtin and mHTT have been shown to modify the disease phenotype in HD models [12] [13] [14] . The partially characterized murine Htt and human HTT promoters have a high GC content and contain a number of consensus binding sites for known TFs, such as Sp1, AP2 and p53 (refs. 15-18) .
To determine whether genetic variation in the HTT promoter influences the transcriptional rate of HTT, we established a panel of HTT promoter reporter constructs originating from HD patients. We identified a SNP (rs13102260:G > A) in a NF-κB binding site that modulated the binding of NF-κB and reduced transcriptional activity of the HTT promoter in reporter gene assays. To investigate this SNP for disease-modifying effects, we assessed HD patient cohorts. We applied family-based designs and extreme phenotype a r t I C l e S sampling (EPS) using case extremes to increase efficiency in testing this candidate SNP for effects on HD AO. We found that familial case and EPS based designs, as compared with random sampling, provided more powerful strategies for testing low-frequency variant effects by enriching for genetic effects [19] [20] [21] . In familial cases, we observed that the minor (A) sequence variant phased to the HD disease allele associated with delayed AO as compared with the (G) sequence variant. In contrast, in our EPS cohort, we found that the (A) variant associated with an earlier AO when phased to the wild-type allele. Finally, we found that the genotype at rs13102260 regulated HTT protein levels, correlating with the observed SNP effects on HD AO. Our in vivo evidence suggests that cis-regulatory variants in the HTT promoter region can act as bidirectional modifiers, influencing AO in HD with allele-specific effects, and this effect was predicted by our in vitro data showing the direct effect of rs13102260 on NF-κB binding and huntingtin expression.
RESULTS

cis-acting variants alter transcriptional activity of the HTT promoter
Genomic regulatory sequences and binding motifs are important for transcriptional regulation. Genetic variants in transcriptional factor binding sites (TFBSs) might affect the binding of TFs and subsequent up-or downregulation of transcription. Recent studies have suggested that transcription rate data is more informative than steady-state mRNA abundance in gene regulation analysis 22 . We engineered a panel of constructs to study the transcriptional activity of the human HTT promoter using the luciferase reporter system. DNA samples from four representative HD patient haplotypes were selected (Supplementary Table 1 ). The human HTT promoter from the YAC128 transgenic mouse model of HD was also cloned and included in the panel 23 . We generated 12 distinct HTT promoter constructs, including the eight alleles from the four HD patients, three pseudoalleles with random PCR-induced sequence variants and one allele from the YAC mouse. We measured basal transcriptional activity of the 12 constructs using the luciferase reporter system in HEK293A cells. We observed similar levels of basal transcriptional activity in 11 of the constructs, whereas construct 5 (a pseudo-allele) exhibited a significant reduction in transcriptional activity compared to the other constructs (t(10) = 4.32, P = 0.0015; Fig. 1a) . Similar experiments were performed in the ST14A cell line, a conditionally immortalized rat striatal cell line displaying similarities to striatal medium spiny neurons 24 , with comparable results (t(10) = 5.83, P = 0.0002; Fig. 1b) . The transcriptional activity of construct 5 was significantly reduced compared with the parental construct 4 (~50%) in both the HEK293A and the ST14A cells. We next sequenced the 3.7-kb HTT promoter region for all 12 constructs (data not shown). Sequence comparison between constructs 4 and 5 revealed ten sequence differences in the non-coding region of the HTT promoter (Fig. 1c) .
Reduced transcriptional activity by the proximal HTT promoter region We used a modified form of the RAVEN bioinformatics software (http://www.cisreg.ca/RAVEN/) to identify putative TFBSs affected by the identified sequence variants. Our results prompted an investigation of known SNPs overlapping the identified binding sites. Four SNPs that overlapped with the putative TFBS in this region were identified: rs35207696, rs28441493, rs184840072 and rs13102260 (Fig. 1c) . rs35207696, rs28441493 and rs184840072 are rare genetic variations with no individual genotype data and no frequency submission. In contrast, the rs13102260 (G > A) occurs in the human population with a minor allele frequency (MAF) (A) = 0.158/792 (1,000 Genomes Project Phase 3; MAF = 0.042 for CEU (Caucasian European); MAF = 0.050 for CHB + JPT (Han Chinese; Japanese) and MAF = 0.441 for YRI (African Yoruban)). We used a sequence-swapping procedure to identify the segment in the promoter of construct 5 responsible for the reduced reporter expression shown in Figure 1a ,b. The 3.7-kb promoter was divided into three consecutive promoter fragments, A, B and C, with fragment C immediately proximal to the HTT translation initiation codon (Fig. 1c) . Each promoter fragment was sequentially swapped between constructs 5 and 4. Swapping the most distal A and B fragments did not alter the baseline transcriptional activity of construct 4 (Fig. 1d) . However, when swapped from construct 5 to 4, fragment C significantly reduced the transcriptional activity of construct 4 to the level of construct 5. In contrast, swapping fragment C from construct 4 into construct 5 conferred normal reporter expression, rescuing the reduced baseline transcriptional activity of construct 5 (F(5,12) = 11.9, P = 0.0003, ANOVA with Bonferroni's multiple comparison test). We next assessed whether fragment C required the distal A and B fragments to be present to have this modulatory effect on expression. Isolated fragment C from both constructs 4 and 5 showed similar levels of transcriptional activity as the full-length constructs from which they originated (F(3,8) = 41.0, P < 0.0001, ANOVA with Dunnett's multiple comparison test; Fig. 1e ). From these results, we conclude that the proximal promoter region of fragment C (~1.1 kb) contains cis-expression QTL (eQTL) that regulate gene expression, and that construct 5 contains genetic variation in this region that substantially reduces HTT expression.
cis-regulatory SNP in NF-kB binding site reduces HTT promoter activity
The alignment between constructs 4 and 5 revealed only three sequence variants in the identified eQTL in the 1.1-kb proximal HTT promoter region. In silico analysis further predicted these sequence variants to overlap with binding sites for CF1/USP, AML-1 and NF-κB (Fig. 1c) . The predicted TFBS, the sequence variant position relative to the translation initiation codon start site, and the sequence variants for constructs 4 and 5 were, respectively: CF1/USP, −763 (T/C); AML-1, −392 (A/G); and NF-κB, −139 (G/T) (Fig. 1c) . We next investigated the functional relevance of altered binding of the identified TFs on transcriptional regulation of the HTT promoter. We performed sitedirected mutagenesis to introduce the three identified construct 5 sequence variants into construct 4. The resulting promoter constructs revealed that changes at the predicted CF1/USP and the AML-1 binding sites did not affect the transcriptional activity in the reporter assay (Fig. 1f) . In contrast, the construct 5 variant of the NF-κB binding motif significantly decreased the transcriptional activity of construct 4C to the levels observed for the construct 5 full-length and fragment C constructs (F(4,19) = 43.6, P < 0.0001, ANOVA with Dunnett's multiple comparison test). The single base-pair difference in the NF-κB binding sites of promoter constructs 4 and 5 was in the tenth and last nucleotide of the TFBS (Fig. 1g) . These results suggest that the construct 5 variant of the NF-κB binding site caused the reduction in transcriptional activity.
We located the rs13102260 (G > A) at the first base position of the NF-κB TFBS consensus motif from our database search on SNPs overlapping the identified putative TFBS in the HTT promoter region (Fig. 1g) . Thus, we identified a SNP that was present in the same NF-κB binding site, but that was distinct from the nucleotide variation that we had originally investigated in vitro. We performed site-directed mutagenesis to introduce the rs13102260 variant into construct 4C to study its effect on transcriptional activity. The rs13102260 (A) variant caused an approximate 50% reduction in transcriptional activity, npg a r t I C l e S similar to constructs 5 and 5C (F(5,14) = 26.2, P < 0.0001, ANOVA with Dunnett's multiple comparison test; Fig. 1h) . Thus, sequence changes at both the first and last position of the NF-κB binding site resulted in significant reduction in transcriptional activity of the HTT promoter.
Activated NF-kB binds to the HTT promoter in vitro and in vivo We next performed a series of biochemical experiments to determine the binding characteristics of the identified TFs and to functionally validate NF-κB binding to the HTT promoter in vitro and in vivo. We performed chromatin immunoprecipitation (ChIP) analysis to study the putative NF-κB occupancy of the huntingtin promoter. Enrichment of NF-κB binding to the predicted TFBSs was assessed using quantitative real-time PCR (qPCR). To investigate whether NF-κB bound the site in vivo, we first performed ChIP using different brain regions of naive mice (Fig. 2a-c) . The mouse Htt promoter contained three putative NF-κB TFBSs within 1,000-bp upstream of the translation initiation codon (Supplementary Fig. 1a ). There was a clear NF-κB enrichment in all of the brain regions and at all of the analyzed TFBS regions comparable to the IL6 promoter control (striatum, F(7,32) = 1.75, P = 0.1336; pre-frontal cortex, F(7,32) = 2.44, P = 0.0401; cerebellum, F(7,32) = 7.22, P < 0.0001; one-way ANOVA). Notably, there was a significantly higher level of NF-κB recruitment in striatum than in pre-frontal cortex and cerebellum at TFBS2 (tissue, F(2,96) = 5.53, To study the NF-κB occupancy on the HTT promoter in a human context, we performed ChIP analysis in lymphoblastoid cell lines (LCLs) derived from HD patients ( Supplementary Fig. 1b ). There was an increased enrichment of NF-κB at the single predicted NF-κB TFBS (comprising rs13102260) in human LCLs (F(3,32) = 4.28, P = 0.0119, one-way ANOVA with Dunnett's multiple comparison test) that was substantially increased compared with a region upstream in the HTT promoter region containing two putative NF-κB TFBSs that we used as controls (−2,065, −2,011 bp from translation start site; Fig. 2e ). Rat striatal ST14A cells, the system employed in the reporter assays, were then stimulated with TNFα to activate the NF-κB pathway. The rat Htt promoter contained four putative NF-κB TFBSs within 1,000 bp upstream of the translation initiation codon (Supplementary Fig. 1c ).
We assessed the binding of NF-κB to the distinct TFBSs using three different primer sets. We observed an enrichment of NF-κB for all three regions that was comparable to the IL6 promoter (F(7,16) = 5.09, P = 0.0034, one-way ANOVA with Bonferroni's multiple comparison test; Fig. 2f) . These results therefore demonstrate an enrichment of NF-κB occupancy at the predicted NF-κB TFBS proximal to the transcriptional start site both in vitro in immortalized rat striatal ST14A cells and in LCLs derived from HD patients, and in vivo in mouse striatum, pre-frontal cortex and cerebellum. Notably, we observed a significantly higher level of NF-κB recruitment in striatum compared to pre-frontal cortex and cerebellum.
rs13102260 alters NF-kB binding to the HTT promoter We used an electrophoretic mobility shift assay (EMSA) to more precisely investigate the interactions between NF-κB and the binding site harboring the rSNP. NF-κB is predominantly cytoplasmic under normal conditions, but migrates to the nucleus following activation by cytokines such as TNFα. We therefore performed TNFα stimulations to activate the NF-κB pathway in ST14A cells before nuclear extract preparation. In the EMSA, NF-κB bound more strongly to the allele 4 compared with the allele 5 oligonucleotide in a concentrationdependent manner (Fig. 3a) . The shifted band was abolished after addition of unlabeled competitor oligonucleotide. The oligonucleotides (allele 5 oligonucleotide in particular) were prone to create secondary structures such as self-dimers or hairpin structures. The NF-κB protein, however, exhibited high affinity for both these secondary structures and the duplexed oligonucleotide (data not shown). In the presence of recombinant human NF-κB p50 protein, a single shifted band was observed that increased in intensity in a concentrationdependent manner, with stronger NF-κB binding to the allele 4 oligonucleotide compared with the allele 5 oligonucleotide (Fig. 3b) . The allele 5 band was out-competed more efficiently with unlabeled competitor oligonucleotide, indicating lower binding affinity to the allele 5 than to the allele 4 oligonucleotide. EMSA confirmed that NF-κB binding to the oligonucleotide containing the rs13102260 (A) variant was fully abolished, as assessed with both ST14A nuclear extract ( Fig. 3c) and recombinant NF-κB p50 protein (Fig. 3d) . The binding of CF1/USP and AML-1 to the allele 4 and allele 5 target sequences was also assessed following incubation with ST14A nuclear extract. None of these showed decreased binding to the allele 5 target sequence (Supplementary Fig. 2 ). The p50/p65 heterodimer is the most abundant of the NF-κB dimers, displaying a very potent gene regulatory function. Different DNA targets determine the final conformation of the heterodimer 25, 26 . The p50/p65 dimer complex specifically recognizes the 5′-GGGRNYYYCC-3′ (R = unspecified purine, N = any nucleotide, Y = unspecified pyrimidine). The p50 subunit strictly recognizes 5′-GGGRN-3′, whereas the p65 subunit recognizes 5′-YYCC-3′, but with less stringency. These results suggest that the p50/p65 heterodimer still binds to both the construct 4 and 5 variants at the tenth base position in the NF-κB TFBSs, but (a-c) ChIP on different brain regions of naive mice was used to investigate whether NF-κB bound the site in vivo. The mouse Htt promoter constitutes three putative NF-κB TFBSs within 1,000 bp upstream of the translation initiation codon. There was NF-κB enrichment at all analyzed TFBS regions comparable to the positive control region for IL6, as assessed by qPCR (striatum, F(7,32) = 1.75, P = 0.1336; prefrontal cortex, F(7,32) = 2.44, P = 0.0401; cerebellum, F(7,32) = 7.22, P < 0.0001; one-way ANOVA, mean ± s.e.m., n = 5). (d) There were significant increases in NF-κB recruitment in striatum compared with prefrontal cortex and cerebellum at TFBS2 (tissue, F(2,96) = 5.53, P = 0.0053; TFBS, F(7,96) = 3.15, P = 0.0049; interaction, F(14,96) = 4.28, P = 0.311; two-way ANOVA). (e) To study the NF-κB occupancy at the HTT promoter in a human context, we performed ChIP analysis in LCLs derived from HD patients. There was enrichment of NF-κB at the predicted NF-κB TFBS containing the rs13102260 in human LCLs (F(3,32) = 4.28, P = 0.0119, one-way ANOVA with Dunnett's test) that was substantially increased compared with a control region upstream in the HTT promoter region containing two putative NF-κB TFBSs (−2,065 and −2,011bp upstream from translation start site; mean ± s.e.m., n = 9). (f) Rat striatal ST14A cells stimulated with TNFα were assessed. Four putative NF-κB TFBSs were identified in the rat Htt promoter within 1,000 bp upstream of the translation initiation codon (TFBS1 containing two predicted binding sites). We observed enrichment of NF-κB at all three regions comparable to what was observed for the IL6 promoter (F(7,16) = 5.09, P = 0.0034, one-way ANOVA with Bonferroni's test, mean ± s.e.m., n = 3). Immunoprecipitation with a normal mouse IgG antibody was used as a negative control. *P < 0.05. npg a r t I C l e S to a lesser extent as a result of reduced binding of the p65 subunit. In contrast, the rs13102260 (A) sequence variant at the first position in the NF-κB TFBS affected the binding of the p50/p65 heterodimer to a higher degree by abolishing the p50 binding to the HTT promoter. These findings demonstrate that sequence variants at the first and last base pair of the NF-κB binding motif in the HTT promoter alter NF-κB binding, subsequently reducing transcriptional activity of the HTT gene.
Targeting of NF-kB modulates HTT expression
We next investigated whether the NF-κB-mediated transcriptional activity on the HTT promoter was dynamic and therefore a potential therapeutic target. We first assessed whether siRNA knockdown of NF-κB influences HTT gene expression. We found that downregulation of NFKB1 and p65 mRNA levels, both of which encode critical components of the potent heterodimer p50/p65 complex, resulted in decreased levels of HTT expression in HEK293 cells (t(12) = 3.53, P = 0.0042; Fig. 4a ). The knockdown of NF-κB was also associated with decreased p53 mRNA levels that were comparable with the decrease in HTT expression, with p53 being an established NF-κB target (t(12) = 3.46, P = 0.0047; Supplementary Fig. 3a) . We next stimulated ST14A cells with TNFα to assess whether the treatment would increase the transcriptional activity of the HTT promoter constructs. Following TNFα stimulation, construct 4 exhibited increased transcriptional activity (F(3,8) = 29.7, P = 0.0001, one-way ANOVA with Dunnett's test), whereas construct 5 exhibited no change in expression compared with the untreated control (Fig. 4b) . Caffeic acid phenethyl ester (CAPE), an active component of propolis from honeybee hives, is known for its immuno-modulatory properties. CAPE blocks TNFα-induced activation of NF-κB in a dose-and timedependent manner by preventing the translocation of the p65 subunit to the nucleus and by selectively inhibiting NF-κB binding to DNA 27 . Stimulation of ST14A cells expressing construct 4 with TNFα in combination with CAPE treatment resulted in reduced transcriptional activity of the promoter in a dose-dependent manner (F(4,7) = 6.24, P = 0.0183, one-way ANOVA with Dunnett's test; Fig. 4c ). We next assessed the effects of CAPE treatment on the basal transcriptional activity of the HTT promoter constructs. Neither constructs 4 nor 5 displayed changes in transcriptional activity levels when the ST14A cells were treated with CAPE in the absence of TNFα ( Supplementary  Fig. 3b ). Western blot analysis was performed to confirm a TNFα-induced increase in nuclear levels of NF-κB protein in our experimental setting. TNFα-stimulated ST14A cell nuclear extract expressed all NF-κB subunits, with the most marked increase being observed in the p50 subunit compared with untreated cells (Fig. 4d) . The cytoplasmic fraction showed strong bands for the precursor subunits p100 and p105, in addition to p50 bands. Western blot analysis revealed that CAPE treatment did not affect the nuclear p65 protein levels in the ST14A cells (Fig. 4d) . Thus, our results suggest that CAPE inhibits NF-κB nuclear activity, perhaps by preventing p65 from binding to the HTT promoter. In summary, we found that TNFα and CAPE stimulations, and siRNA knockdown of NF-κB, modulated the transcriptional activity of the HTT promoter.
rs13102260 (A) variant on HD allele is protective and associated with delayed AO Based on our in vitro findings, we next studied the disease-modulatory effects of the rs13102260 (A) sequence variant in HD patients. We previously showed that a specific HD haplotype was associated with later AO in Danish HD families 28 . We genotyped the familial cases to determine whether the rs13102260 genotype was associated with delayed AO. We performed direct sequencing of HD subjects (n = 98) originating from 36 Danish HD families representing seven different haplotypes, including the one associated with later AO. Direct sequencing revealed that all HD subjects with the B haplotype, previously associated with later AO, exclusively carried the rs13102260 (A) sequence variant. Phasing of the (G) and (A) sequence variants was done in each HD family by segregation of affected and/or unaffected genotypes in the pedigree. We found that the (A) variant phased to the HD disease allele in all B haplotype families (n = 8). 
r t I C l e S
The other HD haplotypes that were not associated with later AO carried the (G) variant. We next performed association testing to further evaluate and quantify the effect of the rs13102260 (G/A) on AO in these HD patients. We restricted our analysis to HD subjects with a CAG length of 41-55, including 35 (G/A) heterozygotes with the (A) phased to the HD disease allele, 41 patients that were (G/G) homozygotes and six (A/A) homozygotes at rs13102260 (n = 82; Supplementary Table 2) . Analysis was performed using weighted least-square models predicting observed AOs as a function of the (G/A) rs13102260 genotype, and expected AO based on the CAG repeat length 8 . The presence of the rs13102260 (A) variant on the HD disease allele had a clear association with HD AO, after first adjusting for CAG-based expected AO (Fig. 5a) . The resulting mean delay of AO was 9.3 years for (A/G) heterozygotes at the mean expected AO in the data (40.1 years) compared with (G/G) homozygotes (t = 5.08, df = 27.1, P = 2.432 × 10 −5 ). The overall rSNP effect (main effect plus interaction) was statistically significant at P = 2.796 × 10 −5 (F = 14.40, df = 2, 34.7). There was evidence for interaction between rs13102260 and the CAG-based expected AO (F = 5.80, df = 1, 73.9, P = 0.0185), with the protective effect being stronger at lower CAG lengths ( Fig. 5a and Supplementary Fig. 4 ). There was, however, no evidence of association in homozygous rs13102260 (A/A) individuals (adjusted mean difference: 5.56 years, t = 1.90, df = 53.4, P = 0.063, n = 6). Thus, we found that the rs13102260 (A) variant has a protective role and is associated with delayed AO when phased to the HD disease allele.
rs13102260 (A) variant on wild-type allele associated with earlier AO
We next genotyped an additional cohort of HD patients (University of British Columbia (UBC) HD Biobank) to validate the observed disease-modulatory effects of the rs13102260 (A) variant on HD AO. We used a family-based design to collect the HD subjects. The patients included in this cohort were assessed individually for age of motor onset, in addition to being mapped into family pedigrees. We further applied an extreme phenotype sampling approach in which we selected the most extreme subject from each pedigree on the basis of AO, using the ratio between observed and expected AO to identify early, mean or late AO HD subjects (Online Methods). This selection of case extremes, similar to familial cases, enriches for alleles that contribute to disease, allowing detection of genotype associations in modest sample sizes 21 . A total of 459 HD subjects were genotyped for the rs13102260 SNP, of which only 28 (approximately 6%, corresponding to MAF in Caucasians) were (G/A) heterozygotes and the remainder were (G/G) homozygotes. We then genotyped relatives of the probands that were identified as (G/A) heterozygotes to phase the (A) variant to the wild-type or the HD disease allele. The rs13102260 (A) variant was almost exclusively on the wild-type allele and thus inherited from the unaffected parent (Supplementary Table 3 ).
As for the Danish cohort, we restricted our analysis to HD subjects with a CAG length of 41-55, including 22 (G/A) heterozygotes with the (A) variant phased to the wild-type allele and 391 subjects that were (G/G) homozygotes (n = 413; Supplementary Table 4) . Analysis was performed using similar weighted least-square models as for the Danish cohort. The presence of the rs13102260 (A) variant on the wild-type allele associated with AO 3.88 years earlier than those with the rs13102260 (G) variant (t = −2.57, df = 367, P = 0.0104; Fig. 5b ).
There was no evidence for interaction between the rs13102260 and the CAG-based expected AO. In addition, given that the UBC data were collected on the basis of AO, with the SNP genotype as the unknown variable being predicted, we also used a logistic regression model to predict SNP genotype as the outcome. The difference between the observed and CAG-based expected AO was the main predictor of Figure 4 Targeting of NF-κB modulates HTT expression. (a) siRNA knock-down of NF-κB in HEK293 cells. Downregulation of NFKB1 (specific for p105, precursor to the p50 subunit) and p65 mRNA levels decreased the levels of HTT mRNA expression, as measured by qPCR (t(12) = 3.53, P = 0.0042, mean ± s.e.m., n = 7). siRNA knockdown efficiency was on average 83% for NFKB1 (t(12) = 16.8, P < 0.0001) and 70% for p65 (t(12) = 7.95, P < 0.0001). One representative data set out of three independent reporter assay experiments is shown for each panel (mean ± s.e.m.). (d) TNFα stimulation of the ST14A cells resulted in increased protein levels of NF-κB subunits as measured by western blot analysis. The p50 subunit increased the most in the nuclear fraction following TNFα stimulation of ST14A cells. The p65 (65 kDa), RelB (68 kDa) and c-Rel (69 kDa) were also increased, but not to the same extent as p50. The cytoplasmic fraction showed strong bands for the precursor subunits p100/p105, in addition to bands for the p50 subunit, which were expressed at similar levels across the different treatments. CAPE treatment had no effect on expression of the NF-κB protein. PARP and β-tubulin show equal loading of protein across lanes for the nuclear and cytoplasmic fractions, respectively. K562, whole cell lysate was used as positive control. Image was cropped for presentation. Full-length blot is presented in Supplementary Figure 9 . *P < 0.05, **P < 0.01, ***P < 0.001. a r t I C l e S allele frequency. Results from this logistic regression were consistent with the results from the above described analysis. The adjustment for expected AO produced estimates of the odds ratio. The odds of having the (A) variant decreased by a factor of 0.929 per year increase in observed AO (F = 5.75, df = 1, P = 0.0165, two-sided Wald test, 95% confidence interval = 0.875-0.987). In other words, the (A) variant phased to the wild-type allele associated with an earlier AO regardless of CAG repeat length. Thus, our results suggest that the rs13102260 (A) variant is a genetic risk variant that accelerates AO in HD patients when phased to the wild-type HTT allele.
It should be noted that we did not have access to additional HD patient data of comparable sample size that are also enhanced by family-based designs or oversampling extreme-phenotype cases. We observed an effect of rs13102260 on AO in two independent cohorts; replication of our findings using carefully selected comparable independent populations will be important. We did attempt a third association study of a random population sample obtained from the European Huntington's Disease Network (EHDN) Registry (n = 26 (G/A), n = 418 (G/G)) for which we did not observe a significant association between AO and the presence of the rs13102260 (A) variant on the wild-type allele (t = 0.58, df = 324, P = 0.5623; Supplementary Fig. 5 ). To the best of our knowledge, no other HD patient population except the Danish cohort has been described to display a high frequency of the rs13102260 (A) variant phased to the HD disease allele. We observed an enrichment of (A) variant carriers with extremely early AO in the UBC population: 41% (9 of 22) of the HD subjects that displayed extremely early AO (<15th percentile) also carried the (A) variant (Fig. 5c) , whereas 15% (4 of 26) of the subjects displaying an extremely early AO carried the (A) in the random EHDN Registry population of a similar size (Supplementary Fig. 5 ). Genotyping familial cases in the Danish cohort also reflected enrichment effects with 26% (9 of 35) of the (A) variant carriers on the HD disease allele displaying extremely late AO (>85th percentile) compared with 9% (40 of 432) in the (G/G) carriers (Fig. 5c) . were categorized according to the AO percentile, given their observed AO and expected AO. A higher proportion of early AO cases was observed in (G/A) carriers with the (A) variant phased to wild-type allele (64%, of which 41% displayed extremely early (x-early) AO below <15th percentile) than in the (G/G) (41%, of which 21% displayed extremely early AO below <15th percentile), whereas a higher proportion of late AO cases was observed in (G/A) carriers (63%, of which 26% displayed extremely late AO above >85th percentile) with the (A) variant phased to the HD disease allele compared to (G/G) carriers (24%, of which 9% displayed extremely late AO above >85th percentile). npg a r t I C l e S Estimation of rs13102260 (A) variant disease modifier effects Association analysis of the UBC cohort revealed that HD subjects with the rs13102260 (A) variant displayed 3.9 years earlier AO compared to HD subjects with the (G) variant phased to the wild-type allele (Fig. 5b) .
In contrast to the UBC cohort, the relationship between CAGrepeat size and expected AO was nonlinear for the Danish cohort as described (P = 0.0185; Supplementary Fig. 4 ). This effect increased by 0.47 years per year of increased expected AO (t = 2.41, df = 73.9, P = 0.0185). The estimated disease-modifying effect of the (A) variant phased to the HD disease allele was greater in HD subjects with shorter CAG repeat lengths ( Table 1) (Fig. 5d) .
rs13102260 (A) variant correlates with distinct haplotype patterns
We next performed sequence analysis of the 22 (G/A) carriers analyzed in the UBC cohort. Notably, sequencing confirmed two distinct haplotype patterns correlating with the rs13102260 (A) variant, including the 6-bp repeat VNTR in the HTT gene promoter and the polymorphic CCG region in exon 1, which have been reported [28] [29] [30] [31] . Of all of the HD subjects with the (A) variant on the wild-type allele, 55% (12/22) carried the two-repeat allele at the 6-bp VNTR loci in conjunction with (CCG) 7 (CCT) 3 at the CCG polymorphic region (alternately referred to as CCG8) (Supplementary Table 5 and Supplementary Fig. 6 ). 45% (10 of 22) carried the one-repeat allele of the 6-bp VNTR locus in conjunction with (CCG) 7 (CCT) 2 at the CCG polymorphic region (alternatively referred to as CCG7). Previous studies showed that the copy number at the 6-bp VNTR loci by itself did not affect transcriptional activity 15 . Notably, the haplotype carrying the rs13102260 (A) variant, the two-repeat alleles at the 6-bp VNTR loci and CCG8 on the wild-type HTT allele that was represented in the (G/A) heterozygotes in the UBC cohort that associated with earlier AO corresponded to the haplotype on HD disease alleles in the Danish HD families that we previously reported to be associated with delayed AO 28 .
Genotype at rs13102260 regulates allele-specific expression of HTT protein Finally, we assessed whether the genetic variation at rs13102260 modulates protein levels in HD patient fibroblast lines. We compared HD patient fibroblast lines with different genotypes at rs13102260: homozygous (G/G), heterozygous with (A) variant phased to the wildtype allele or heterozygous with (A) variant phased to the HD disease allele. The (A) variant significantly downregulated HTT protein levels when phased to the wild-type allele (t(6) = 3.27, P = 0.0169; Supplementary Fig. 7 ). The HTT levels were reduced by approximately 50%, which corresponds to the reduction observed in transcriptional activity (Fig. 1h) . As expected, the (A) variant also significantly downregulated mHTT protein levels when phased to the HD disease allele (~25% decrease, t(6) = 2.46, P = 0.0495; Supplementary Fig. 7 ).
We observed a general reduction of mHTT protein levels compared with the wild-type protein regardless of genotype. This allele-specific expression difference might be explained by intrinsic tissue-specific regulation, epigenetic modifications or HD haplotypes that might contain cis-regulatory elements influencing gene regulation. Thus, we found that the (A) variant is a modifier of protein levels; the (A) variant phased to the wild-type allele significantly reduced wild-type HTT protein levels, whereas the (A) variant phased to the HD disease allele reduced the levels of mHTT protein. These results reveal functional consequences of this cis-acting regulatory variant that altered NF-κB binding, reduced HTT protein levels and associated with modulation of AO in HD patients (Supplementary Fig. 8 ).
DISCUSSION
Genetic disease modifiers cause single-gene diseases such as HD to display features of complex traits by influencing the disease expressivity 32, 33 . We identified a cis-acting rSNP in the HTT promoter that acts as a bidirectional genetic modifier in HD. We found that rs13102260 (G > A) exerted allele-specific modifier effects on AO in HD patients by decreasing NF-κB binding to the HTT promoter, resulting in reduced HTT expression. Association analyses demonstrated the disease-modulatory effects of rs13102260 (G > A) on AO in HD. Biochemical analysis further validated the potency of this cis-acting genetic variant by measuring its allele-specific effects on transcriptional activity, TF binding and protein expression. To put our results into clinical context, patients with the (A) variant phased to the HD disease allele developed motor symptoms on average 10 years later than HD patients with the (G) sequence variant. Notably, the estimated disease-modifying effect was greater in HD subjects with shorter CAG repeat lengths and declined with increased CAG repeat length ( Table 1) . In contrast, we further found, in an independent cohort, that patients with the (A) variant on the wild-type allele were estimated to develop HD motor symptoms almost 4 years earlier than patients with the (G) variant.
Identification of genetic modifiers in HD is important for two reasons. First, these genes and related pathways are excellent potential therapeutic targets in HD. Second, these modifiers may [34] [35] [36] [37] [38] . Cis-regulatory genetic variants that alter gene expression are a potential source of phenotypic difference thought to be important for the pathogenesis of many complex diseases, but none have been identified in HD thus far. Recently, a genome-wide study focusing on NF-κB (p65) binding sites showed that genomic structural variants, such as SNPs, frequently cause differences in gene expression as a result of altered binding of NF-κB 39 .
Although NF-κB is nearly ubiquitously expressed, its role in neurons of the CNS is controversial 40 . We found that NF-κB regulation of the HTT promoter was dynamic using both siRNA knockdown of NF-κB and cytokine stimulations and inhibitors. Notably, we also observed an increase in NF-κB activity in striatum in naive mouse brain, which is the brain region primarily affected in HD. Our results indicate that NF-κB directly binds to and increases the transcriptional activity of the HTT promoter, providing the potential for a toxic feedback loop that could result in a detrimental increase in expression of mHTT in striatal neurons. Given the selective effects of HD pathogenesis in the striatum, our finding that NF-κB activity was significantly increased in striatum in naive mouse brain suggests that the interaction between NF-κB and HTT merits additional investigation.
Genome-wide studies have demonstrated that allelic imbalance is common 41 . We found that the rs13102260 (A) variant leads to increased allelic imbalance. Recent studies have suggested that there is allelic imbalance, as mutant HTT mRNA is more abundant than the wild-type mRNA in post-mortem HD striatum and cortex, whereas there is no difference in the cerebellum 42 . Increased levels of mHTT are associated with increased sensitivity to excitotoxicity, earlier AO and more rapid disease progression in the YAC128 mouse model of HD 12 . Notably, decreasing the levels of wild-type HTT increases the cellular toxicity of mHTT 13, 14 , and overexpression of wild-type HTT ameliorates striatal neuronal atrophy 43 . The balance between wildtype and mutant HTT could be thought of as a 'yin-yang' relationship (Supplementary Fig. 8 ). Calculations on the estimated rSNP effect further suggest that the cis-regulatory (A) variant exerts a much greater disease-modifying effect on AO when phased to the HD disease allele compared with the wild-type HTT allele. Our in vivo results in HD patients therefore indicate that reduction of mHTT is a more potent disease modifier of AO than reduction of wild-type HTT. HD subjects with CAG repeat lengths of 43 presented AO on average 13.1 years later than expected ( Table 1) . This has implications not only for our understanding of the interaction between wild-type and mutant HTT, but also for the gene silencing strategies applied in HD. Thus, our results highlight the importance of continued refinement of our understanding of allelic imbalance in HD patients.
HD is a single gene disorder thought to be mediated by a toxic gain of function, and silencing of HTT expression is an attractive therapeutic approach. Studies performed in mice have suggested that nonallele-specific silencing alleviates HD symptoms, whereas other studies have provided support for allele-specific silencing in HD 44 . Our results suggest a disadvantage of lower wild-type HTT levels and, as most HTT silencing studies have been relatively short-term and performed in mouse, a potential issue is whether non-allele-specific silencing may have undesirable longer term effects by decreasing levels of wild-type HTT. Our study nevertheless provides, to the best of our knowledge, the first clinical evidence that HTT gene silencing therapies for HD will be efficacious. If these therapies are not allele specific, we predict that they will have a net beneficial effect, but that allele-specific approaches targeting mHTT may have greater therapeutic efficacy.
Here we identified NF-κB as a trans-acting factor that regulates HTT gene expression and rs13102260 to act as a bidirectional modifier of AO in HD. We refined the notion of allele-specific relationships between cis-acting regulatory elements, the transcriptional rate of HTT expression and AO in HD subjects. In conclusion, our results have implications for therapeutic strategies aimed at silencing of the HTT gene in HD patients. Genotyping of rs13102260 may further provide relevant prognostic information for a subset of HD gene carriers. Continued identification of cis-and trans regulatory elements will provide insights into their effect on disease expressivity and identify new targets for disease-modifying therapeutic interventions in HD.
METHODS
Methods and any associated references are available in the online version of the paper. 
